Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06396598
Other study ID # OSU-23149
Secondary ID NCI-2024-00269
Status Recruiting
Phase N/A
First received
Last updated
Start date February 9, 2024
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Ohio State University Comprehensive Cancer Center
Contact The Ohio State Comprehensive Cancer Center
Phone 800-293-5066
Email OSUCCCClinicaltrials@osumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial evaluates earlier symptom management through remote electronic symptom monitoring (such as through an app on patient's phone), and accessibility of palliative care self-referral by patients with thoracic cancer and caregivers by proxy (legal representative). Thoracic cancer occurs in the chest and often causes symptoms for patients. Patients and/or their caregivers are often unable to attend in-person clinic visits for various reasons. The most frequently reported symptom by patients at initial palliative care consultations is pain, and caregivers' most common concerns are pain management for the patient, stress reduction, and fears about patient decline. Earlier palliative care referral can help control these symptoms before they worsen, providing a better quality of life for patients and caregivers. improve physical and emotional functioning for patients and caregivers in cancer care. This study may help researchers learn how an electronic symptom monitoring program may provide an earlier and more accessible way for patients with thoracic cancer to receive palliative care.


Description:

PRIMARY OBJECTIVE: I. Develop and assess feasibility of a remote electronic symptom monitoring program with a prompted option for palliative care self-referral for patients or caregivers by proxy after diagnosis of a thoracic malignancy. SECONDARY OBJECTIVE: I. Evaluate palliative care referral patterns after implementation of a remote electronic symptom monitoring program. OUTLINE: Patients and their caregivers use the electronic symptom monitoring program to log symptoms once a week (QW) for 24 weeks. Patients and their caregivers also watch a video and review education materials prior to starting the remote symptom monitoring program. After completion of study intervention, participants are followed up to 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 157
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - PATIENTS: Age = 18 years - PATIENTS: Diagnosed with any stage (1-4) or type (non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic carcinoma) of thoracic malignancy - PATIENTS: = 2 visits at the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic - PATIENTS: Study enrollment within 12 weeks of initial Thoracic Medical Oncology appointment - PATIENTS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means) - PATIENTS: Ability to read and understand English - PATIENTS: Access to a device with email or text messaging capability - CAREGIVERS: Age = 18 years - CAREGIVERS: Identified by patient participant as primary caregiver - CAREGIVERS: Corresponding patient participant has consented to participate in the study - CAREGIVERS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means) - CAREGIVERS: Ability to read and understand English - CAREGIVERS: Access to a device with email or text messaging capability Exclusion Criteria: - PATIENTS: Patients who have been previously referred to ambulatory palliative care are excluded from participation - PATIENTS: Prisoners are excluded from participation - PATIENTS: Pregnant patients are excluded from participation - PATIENTS: Patients who lack capacity for medical decision-making as determined by their primary oncologist are excluded from participation - PATIENTS: There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, prior cancer diagnoses, presence of comorbidities or brain metastases

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Educational Activity
Review education materials
Electronic Health Record Review
Ancillary studies
Internet-Based Intervention
Participate use the electronic symptom monitoring program to log symptoms
Media Intervention
Watch a video
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center National Comprehensive Cancer Network

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of symptom logging Will estimate that = 50% of patient participants will log symptoms at least monthly through the remote electronic symptom monitoring program. At 6 months after enrollment
Primary Proportion of patients enrolled (Feasibility) Descriptive statistics will include study enrollment rates (eligible vs. ineligible participants, consented vs. refused), completion rate of weekly symptom monitoring (patient vs. caregiver by proxy), and person requesting palliative care services (patient vs. caregiver by proxy vs. medical provider), if applicable. Will be considered feasible if within 20% of target enrollment. At enrollment and 3 months
Primary Symptom scores and Palliative Referral Association Symptom scores (Edmonton Symptom Assessment Scale revised with Constipation and Sleep [ESAS-r-CS]) reported by patients and caregivers will be tracked and their association with palliative care referral, if applicable, will be assessed. At enrollment and 3 months and 6 months
Primary Patient and Caregiver Symptom Reporting Congruency Descriptive statistics will be used to assess for congruency between patient and proxy-reported symptom assessments. Patients' oncologic treatment (chemotherapy, immunotherapy, radiation therapy, surgery) will be abstracted from the electronic medical record (EMR) at the time of each ESAS-r-CS survey completed by either the patient or caregiver by proxy. At enrollment and 3 months and 6 months
Secondary Palliative care referral patterns Palliative care referrals pre- and post- launch of the SyMPLER study will be evaluated for trends. Historical control data collecting palliative referrals by month will be compared between groups (pre-post- launch). Up to 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Recruiting NCT06456411 - Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
Active, not recruiting NCT03868579 - Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy N/A
Recruiting NCT04963972 - Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery N/A
Completed NCT05793957 - Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms N/A

External Links